A pioneering clinical trial led by Neuroscience Research Australia has found that intranasal insulin could offer a promising new treatment for delirium, potentially reducing hospital stays for older patients by several days and addressing a significant gap in care.

Emyria (ASX:EMD) has secured expanded funding support from Medibank Private for patients accessing its treatment-resistant depression and post-traumatic stress disorder programs, marking a significant step in the company’s national growth strategy.

Senior Victorian Government representatives will headline flagship events at this year’s AusBiotech International Conference 2025 and AusBiotech Invest Conference 2025 in Melbourne, highlighting the state’s growing leadership in biotechnology and life sciences.

A clinical trial led by Professor Louise Emmett at St Vincent’s Hospital, Sydney, has achieved its primary endpoint, showing that 64Cu-SAR-bisPSMA detects significantly more prostate cancer lesions than the current standard-of-care PSMA PET imaging in men with low PSA levels.

Melbourne nano-biotech Nexsen (ASX:NXN) will debut on the ASX with its world-first biosensing platform that brings lab-grade diagnostics to the point of need.

Medical Developments International (ASX:MVP) used its 2025 AGM to draw a clear line under its rebuild and set out a confident growth agenda.

PYC Therapeutics (ASX:PYC) is advancing its Phelan-McDermid syndrome (PMS) program toward first-in-human studies, reporting non-human primate results that, along with earlier patient-derived neuron data, support progression to the clinic.

Adherium (ASX:ADR) has launched an Early Exercise Incentive Offer that rewards eligible optionholders who subscribed under the company’s placement and accelerated non-renounceable entitlement offer.

Adherium (ASX:ADR) has launched an Early Exercise Incentive Offer that rewards eligible optionholders who subscribed under the company’s placement and accelerated non-renounceable entitlement offer.

The program has been unveiled for the AusBiotech International Conference 2025, confirming the most ambitious lineup in the event’s history, with over 60 sessions and 250 speakers set to gather the global life sciences community in Melbourne from 21 to 24 October at the Melbourne Convention and Exhibition Centre.

Australia’s leading life sciences incubator, CUREator, delivered by Brandon BioCatalyst in partnership with CSIRO, has opened applications for a new $33 million BioMedTech Incubator (BMTI) funding round.

Immuron (ASX:IMC) has submitted an Investigational New Drug application to the US FDA for its proprietary oral therapy IMM-529, marking a significant milestone in the company’s effort to combat one of the world’s most persistent and dangerous bacterial infections.

Percheron Therapeutics (ASX:PER) has announced final results from its Phase I clinical trial of HMBD-002, a novel immunotherapy targeting multiple forms of advanced cancer, showing a strong safety profile and early signs of clinical activity.

NeuroScientific Biopharmaceuticals (ASX:NSB) has reached a significant milestone in its clinical development program, announcing TGA approval for the first three patients to receive its proprietary stem cell therapy, StemSmart, under Australia’s Special Access Program for the treatment of fistulising Crohn’s disease.

Neurizon’s Managing Director and CEO, Dr Michael Thurn, described the FDA’s clearance as “a defining moment” for the company’s mission to accelerate access to innovative therapies for people living with ALS.

Australian biotechnology company Cyteph has announced the completion of recruitment for its first-in-human Phase 1 clinical trial of CYT-101, a groundbreaking off-the-shelf, HLA-matched CMV-specific T cell therapy being developed to treat recurrent glioblastoma multiforme.

Dimerix (ASX:DXB) has received final data from the PARASOL collaboration, reinforcing support for the company’s proteinuria-based endpoints in its Phase 3 ACTION3 study for Focal Segmental Glomerulosclerosis.

Australia’s Life Sciences Innovation Accelerator, MTPConnect, has announced a landmark strategic partnership with Wholesale Investor, one of the region’s leading private capital marketplaces, to help bridge the country’s most persistent gap in the commercialisation pipeline.

AusBiotech has released its 2024–25 Annual Report, marking what Chair Dr James Campbell described as a “transformational and defining year” for the organisation and Australia’s broader life sciences community.

The countdown is on to Australia’s biggest week in biotechnology, and with it comes a unique opportunity to forge connections that could shape the future of health and innovation.

AusBiotech CEO Rebekah Cassidy said the organisation applauds the government’s commitment to reform, describing it as a “once-in-a-generation opportunity” to secure Australia’s global leadership in clinical research.